^
    6d
    D702KC00001: A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) (2024-519786-22-01)
    P1/2, N=43, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    Cyramza (ramucirumab) • rilvegostomig (AZD2936)
    7d
    Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, Diwakar Davar | Recruiting --> Active, not recruiting | N=26 --> 8 | Trial completion date: Jan 2031 --> Jan 2030 | Trial primary completion date: Jan 2028 --> Feb 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    BRAF mutation
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    9d
    AB02: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=186, Recruiting, AstraZeneca | N=89 --> 186
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    13d
    D702NC00001: A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy in adults with advanced biliary tract cancer (2025-523085-24-00)
    P2/3, N=89, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    14d
    ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1/2, N=212, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    rilvegostomig (AZD2936)
    15d
    INDIGO: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures (clinicaltrials.gov)
    P2, N=0, Withdrawn, Gustave Roussy, Cancer Campus, Grand Paris | N=115 --> 0 | Trial completion date: Jan 2030 --> Sep 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2028 --> Sep 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    20d
    GEMINI-Gastric: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=163, Recruiting, AstraZeneca | N=240 --> 163 | Trial completion date: Sep 2027 --> May 2029 | Trial primary completion date: Jul 2026 --> Nov 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    20d
    KEYMAKER-U04 Substudy: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (clinicaltrials.gov)
    P1/2, N=49, Completed, Merck Sharp & Dohme LLC | N=37 --> 49
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    21d
    ARTEMIDE-subQ: A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca
    Trial initiation date
    |
    rilvegostomig (AZD2936)
    21d
    VELOCITY-Lung: Study of Novel Treatment Combinations in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=270, Recruiting, Gilead Sciences | N=593 --> 270
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)
    22d
    TROPION-Lung10: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=675, Recruiting, AstraZeneca | Trial completion date: May 2030 --> Dec 2029 | Trial primary completion date: Apr 2028 --> Dec 2029
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK rearrangement • ROS1 rearrangement
    |
    Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    24d
    Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1. (PubMed, Lung Cancer)
    Adding Fc-silent anti-TIGIT (domvanalimab) to anti-PD-1 (zimberelimab) led to encouraging efficacy and showed no new safety concerns in patients with previously untreated stage IIIB-IV NSCLC.
    P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)